Sandra has nine years’ of research and consulting experience in health economics from both HTA and consulting perspective, specializing in health economic modeling and evaluations. She has advanced modeling training and has expertise in the development of a range of modeling types, with a main area of interest in cost-effectiveness analyses. Her work spans a number of disease areas, including neurological disorders, rare diseases, oncology and cardiovascular disease.
Before joining Evidera, Sandra worked at the Canadian Agency of Drugs and Technologies in Health (CADTH) conducting HTA reviews of a number of health economic evaluations submitted by drug manufacturers through Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) for public plan listings, as well as working on the development of health economic models. Sandra holds a bachelor of science in pure mathematics from the University St. Cyril and Methodius, Skopje, Macedonia, and a master of science in systems science from the University of Ottawa, Canada